WCLC 2022 – Julia Rotow
Julia Rotow summarizes the achievements of EGFR tyrosine kinase inhibitors in the neoadjuvant therapy of lung cancer regarding multiple clinical outcomes, discusses if modification of the disease biology will be a feasible treatment goal in the setting of EGFR-directed neoadjuvant treatment sometime and talks about the individualization of neoadjuvant treatment of oncogene-driven lung cancer.
Here is the full WCLC 2022 report.
More posts
Ovarian cancer: taking PARP inhibition one step further
Ovarian cancer: taking PARP inhibition one step further Individualized dosing o
Getting innovation from the laboratories into clinical practice
Getting innovation from the laboratories into clinical practice Andrés Cervantes
Milestones of PD-1 inhibition in gastric and esophageal cancer
Milestones of PD-1 inhibition in gastric and esophageal cancer Gastric cancer,
Preface – ESMO 2020 Solid Tumors
Preface – ESMO 2020 Solid Tumors Ronan Kelly, MD, MBA – Director of the
